Cantel Medical — Investor Presentation (January 2015)
21 slides from Cantel Medical's investor presentation, Jan 15, 2015
Slide 1: Investor Presentation, January 15, 2015
FORWARD LOOKING STATEMENT This presentation contains forward-looking statements. All forward-looking statements involve risks and uncertainties, including, without limitation, the risks detailed in the Company’s filings and reports with the Securities and Exchange Commission. Such statements are onl
Slide 2: Cantel Medical Overview
Cantel Medical Overview The only pure-play in the growing ~$50B Global Infection Prevention & Control Market (“IP&C”) with existing businesses in addressable markets of approximately $6B Government and industry focus on IP&C is a growth driver and largely shields our markets from downward/weak econo
Slide 3: Our Mission Statement
Our Mission Statement Our Purpose Cantel Medical is dedicated to delivering innovative infection prevention and control (IP&C) products and services for patients, caregivers, and other healthcare providers, which improve outcomes and help save lives. Our Business Priorities New Products: Continually
Slide 4: Cantel Medical Facilities
Cantel Medical Facilities 40 locations in the North America Netherlands Singapore China United Kingdom 1,700 Dedicated Global Employees Italy 4
Slide 5: Category Leadership and Strong Performance
Endoscopy Leader in automated endoscope reprocessing systems and procedural disposable products Water Purification & Filtration: Leading share in water purification systems to dialysis facilities as well as a suite of sterilants and filtration products Healthcare Disposables: Leading branded portfol
Slide 6: Three Major Synergistic Segments
Three Major Synergistic Segments Infection Prevention & Control Focus Endoscopy Endoscopy Reprocessing & Procedure Room Products Water Purification & Filtration Medical & Life Science Water Purification & Filters Healthcare Disposables Dental, Hospital, Sterility Assurance Chemistries, Manufacturing
Slide 7: Well-Balanced Portfolio: Three Major Segments
Well-Balanced Portfolio: Three Major Segments Last 12 Months Ended October 31, 2014 Net Sales $507.3M Operating Income $88.5M1 “All Other” includes Specialty Packaging Products. 1 Before allocation of corporate expenses of ~$16.9M. 2 Earnings Before Interest, Taxes, Depreciation, Amortization, Stock
Slide 8: Long-term Track Record of Strong Growth & Margin Expansion
*FY’11 Net Debt includes $98M in debt assumed on the first day of fiscal year 2012 upon closing of the Byrne Medical acquisition. Long-term Track Record of Strong Growth & Margin Expansion CAGR ’03 – ’14 16% 21% 8 Strong cash flow generation funds acquisition program with modest leverage
Slide 9: Sustainable Growth Strategy Driven by Four Key Principles
New Products Sustainable Growth Strategy Driven by Four Key Principles CONTINOUS IMPROVEMENT Market Expansion Strategic Acquisitions 9
Slide 10: Market Expansion: Significant Global Investment in Sales & Marketing
Market Expansion: Significant Global Investment in Sales & Marketing OR, central sterile, physicians offices, GI–Adenoma detection, etc Endoscopy expansion complete Water and HC disposable teams expanding Accelerating investments Go-direct in UK, Germany, Italy and China Total spending in S&M has mo
Slide 11: New Products: Accelerated Investments in R&D Pipeline
New Products: Accelerated Investments in R&D Pipeline Product development has grown by more than 2.5x over the last five years Endoscopy Portfolio Chemistry Portfolio Water Purification & Filtration Portfolio Healthcare Disposables Portfolio Broadest range of endoscope reprocessors (AERs) Now launch
Slide 12: Strategic Acquisitions: Investing in all Core Segments & International Capabilities
Strategic Acquisitions: Investing in all Core Segments & International Capabilities Proven ability to successfully integrate, leverage & grow acquired businesses Endoscopy Water Purification & Filtration Healthcare Disposables Byrne Medical, PuriCore (UK), IMS (Italy), JetPrep New products, new mark
Slide 13: Long-term Growth Drivers: Endoscopy
Long-term Growth Drivers: Endoscopy Large and growing global addressable market totaling >$4 billion Colorectal cancer is a leading global cause of death, driving worldwide screening and treatment efforts Improved adenoma detection rates will accelerate colonoscopy procedures Single-shot AERs drive
Slide 14: Long-term Growth Drivers: Water Purification & Filtration
Long-term Growth Drivers: Water Purification & Filtration End Stage Renal Disease patient demographics drive de novo clinic build in the US Market adoption of heat-based water disinfection technology platform Improved IP&C standards for dialysis patients, labor savings to facility operators Upgrade
Slide 15: Long-term Growth Drivers: Healthcare Disposables
Long-term Growth Drivers: Healthcare Disposables Leading branded player in the US dental market Sterility assurance category adds high growth, higher margin platform Hospital channel presence to drive sales of entire healthcare disposables product portfolio Innovative high margin face masks / pandem
Slide 16: Experienced Executive Team
Experienced Executive Team Andrew A. Krakauer Chief Executive Officer Jorgen B. Hansen President & Chief Operating Officer Eric W. Nodiff Exec. Vice President General Counsel Craig A. Sheldon Exec. Vice President Chief Financial Officer & Treasurer Seth M. Yellin Sr. Vice President Corporate Develop
Slide 17: Historical P&L Reveals Success of Growth Programs
Historical P&L Reveals Success of Growth Programs 1 Earnings before Interest, Taxes, Depreciation, Amortization, and Stock Compensation Expense. 2 Retroactively applies the 3:2 stock splits effective February 2012 and July 2013. 3 Compound Annual Growth Rate. 4 Last twelve months ended October 31, 2
Slide 18: Strong Balance Sheet & Cash Flow Generation
Strong Balance Sheet & Cash Flow Generation 1 For last twelve months ended October 31, 2014. 2 Earnings before Interest, Taxes, Depreciation, Amortization, and Stock Compensation Expense. 3 Retroactively reflects 3:2 stock splits effective February, 2012 and July, 2013. 18 1 ($ and shares in million
Slide 19: Strategic Objective: Double Sales & EPS from FY13 to FY18
Strategic Objective: Double Sales & EPS from FY13 to FY18 Successfully completed year one of plan Continued investments in high growth, high margin product lines Focus on channel expansion including international and hospital markets Execute proven acquisition program to accelerate global growth Acc
Slide 20: Cantel Medical - Summary
Cantel Medical - Summary $507M NYSE Specialty Infection Prevention & Control Leader1 Strong, recession-buffered core business with high future growth prospects 73% recurring revenue and $97.5M in LTM EBITDAS1 25 successful acquisitions since 2000 Investments in new product development and increased
Slide 21: Thank You!
% CANTEL MEDICAL THANK YOU!
Cantel Medical — Investor Presentation (January 2015) on 6ix